We recently published 14 Stocks Jim Cramer Discussed As He Talked About Record Bitcoin Price. Hims & Hers Health, Inc.

What Happened? Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 4.1% in the morning session after the ...

Hims & Hers Health reports 111% Q1 2025 revenue growth to $586M, driven by personalized treatments & strong margins. Read why ...

Hims & Hers, the high-flying online health company that rapidly grew from a buzzy startup selling Viagra to a ...

Hims & Hers Health (HIMS) is quickly becoming one of the most compelling stories in the market as an emerging powerhouse in the direct-to-consumer healthcare space. The stock has posted outsized gains ...

Hims & Hers Health (NYSE: HIMS) is a telehealth company that offers personalized solutions for its customers. While ...

Analysts said the deal with Novo was likely giving Hims “‘credibility’ or increased consumer traffic,” adding that the ...

Hims & Hers Health Inc HIMS shares surged in early trading Wednesday before pulling back. The stock was still up marginally at last check after the company announced a planned Canadian expansion.

Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a ...

Hims & Hers Health plans to expand into Canada, timing it with the new availability of the generic weight loss medication on the market for the first time.

The move follows a dramatic breakup in June between Hims & Hers and Danish drug maker Novo Nordisk, which makes the brand name weight loss drug Wegovy. Novo Nordisk accused the Hims & Hers of ...

Hims & Hers Health is up 94.2% since the beginning of the year, but at $48.95 per share, it is still trading 28.8% below its 52-week high of $68.74 from February 2025.